Zhenggang Ren

Transarterial Chemoembolization with Durvalumab or Durvalumab + Bevacizumab in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...

Shukui Qin , MD, PhD;

Zhenggang Ren ;

Joseph Erinjeri ;

Shethah Morgan ;

Gordon Cohen ;

Yasuaki Arai , MD;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Stephen Lam Chan , MD;

Masatoshi Kudo , MD, PhD;

10/21/2019

CIO 2020-4 Transarterial Chemoembolization Combined With Durvalumab±Bevacizumab in Patients With Locoregional HCC (EMERALD-1)

Yasuaki Arai , MD;

Zhenggang Ren ;

Joseph Erinjeri ;

Philip He ;

Shethah Morgan ;

Gordon Cohen ;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Masatoshi Kudo , MD, PhD;

Stephen Lam Chan , MD;

Shukui Qin , MD, PhD;

07/23/2021

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

Zhenggang Ren

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products